


Biotech entrepreneur and consultant. Biochem PhD. Opinions strictly my own.



I built my Biologics COGS Estimator (biologics.tools) because I found I (and my peers) often need a quick, defensible manufacturing cost figure without paying a consultant for an hour of time. What you've been using in the existing, free version remains free and always will be. Now, I'm happy to share I've launched a Pro version for additional functionality. Pro adds: • Monte Carlo simulation: 10,000 runs give you a P10/P50/P90 cost range instead of one point estimate • A tornado chart showing which assumptions (e.g., titer, yield, resin, facility cost) move your cost most • Side-by-side comparison of up to 3 scenarios The core calculator, saved scenarios, and exports remain free. Pro is $50/month or $500/year. The default Monte Carlo ranges are my own judgment and every one is editable. Please let me know any feedback or requests!

Congrats to Romesh and team! Marrow Therapeutics Launches with $173 Million to Develop Genetic Medicines for Bone Marrow Disorders marrowtx.com/news/marrow-the…

BIO CEO: American biotech needs a coordinated plan to beat China — now statnews.com/2026/11/10/chin… via @statnews

Oh and DYN 3.8 s vHOT improvement over placebo was with lowest dose, 1.8 mpk, versus 10 mpk for PEPG

Exciting Ph 2 data from $PEPG today. Just be cautious comparing splicing correction across studies (is their 22-gene panel the same as Dyne CASI?), and note PEPG and DYN have the same vHOT results (3.9 and 3.8 s vs. placebo), though only n=6 for PEPG [no position in either]

This is incredible. Datasets appear to be highly relevant and accurate based on a couple quick tests. Wow!
Very excited to introduce Paperclip Datasets! Curate your own datasets from millions of papers in minutes. Just describe the dataset you want to build! As example, we release the largest dataset of 20k half-life human measurements curated from 2400+ drugs💊 🖇️ Try it: paperclip.gxl.ai/datasets 📝 Blog: gxl.ai/blog/introducing-pape… 📊 Half-life dataset: huggingface.co/datasets/gxl-…

Wow big acquisition in the CDMO space. 5 sites, 1100 employees, "low-to-mid triple-digit M CHF" price. Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence lonza.com/news/2026-11-03-07…

New post from Anthropic on what they've been up to in biopharma. Some interesting projects Early progress on accelerating drug development with Claude anthropic.com/research/early…

Poll for biotech entrepreneurs and biotech/pharma BD folks: What do you use for your fundraising or BD tracker? I personally use excel, which I kind of hate. If you use software or SaaS, please reply with the name. Thanks!

IMO… it is a mistake to “try to increase U.S. competitiveness through protectionism.” The new rule “may make it easier for non-U.S. companies to succeed through manufacturing in China. This wouldn’t help our global competitiveness.” IMO… let’s instead kick ass with American ingenuity! biocentury.com/article/66129…


Buyout firm EQT to acquire Qiagen for $10.8 billion reuters.com/legal/transactio…

Love the idea of modular fill/finish facilities/pods - Mark Cuban wants to crack open the market for rare disease treatments statnews.com/2026/10/21/mark…

Go Wayne!
Estuary Biotherapeutics is on a mission to make #ADPKD history through targeted gene therapies designed to address the disease’s underlying genetic cause. Led by CEO Wayne Sackett and built on landmark discoveries from scientific co-founders Stefan Somlo, MD, and Michael Caplan, MD, PhD, at @YaleMed, we're launching with $103 million to advance our lead programs, EST-201 and EST-101, toward clinical proof of concept. Watch our story and learn more at estuarybio.com. estuarybio.com/news/estuary-…